ACAlberto Cebrian-Serrano

Alberto Cebrian-Serrano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alberto Cebrian-Serrano has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Endogenous Gdf15 activation limits adiposity and increases fecal energy excretion in mice

    by Maximilian Kleinert, Sarah Engelbeen, Kornelia Johann, Casper Sigvardsen, Franziska Sörgel, Alina Blenninger, Christopher Bishop, Christian Voldstedlund, Soeren Ocvirk, Joan Pasano, et al.

    Growth differentiation factor 15 (GDF15) is an emerging target for obesity, but the effects of sustained physiological increases in endogenous GDF15 remain unclear. Here we use muscle-targeted CRISPR activation to elevate endogenous Gdf15 expression in mice. High-physiological circulating GDF15 prevents diet-induced obesity by limiting fat accumulation while preserving lean mass. This protection requires the endogenous Gdf15 locus and GFRAL signaling, without a detectable increase in energy expenditure. Alongside modest, inconsistent reductions in food intake, Gdf15 activation increases fecal energy excretion, accompanied by gut microbiota remodeling and altered ileal transcriptional programs. In mice with established obesity, Gdf15 activation reduces adiposity and increases fecal energy excretion without a detectable reduction in food intake. These findings identify fecal energy excretion as a GDF15-regulated component of energy balance and support a role for endogenous GDF15 beyond appetite regulation.

  • Open Access

    Endogenous Gdf15 induction promotes obesity resistance by augmenting energy excretion

    by Maximilian Kleinert, Sarah Engelbeen, Kornelia Johann, Casper Sigvardsen, Franziska Sörgel, Alina Blenninger, Christopher Bishop, Christian Voldstedlund, Soeren Ocvirk, Joan Pasano, et al.

    Growth differentiation factor 15 (GDF15) is a hormone-like factor that has emerged as a potential therapeutic treatment of obesity. Pharmacological studies have shown that high, supraphysiological doses of recombinant, mature human GDF15 decrease food intake in obese mice; yet, the metabolic impact of physiological elevations in endogenous GDF15 are unknown. Here, we delivered CRISPR activation (CRISPRa) via muscle-targeting viral vectors in mice to upregulate endogenous Gdf15 expression, resulting in a five- to eight-fold increase in circulating GDF15 levels, comparable to that seen after prolonged exercise or with aging. This physiological elevation in circulating GDF15 conferred resistance to diet-induced obesity by selectively preventing fat mass accumulation without detrimental impact on lean mass and in the absence of aversion-like behavior typically observed with high GDF15 levels. The anti-obesity effect was Gdf15 locus-specific, dependent on the GDF15-receptor, GFRAL, and occurred without changes in energy expenditure of mice. Instead, elevated circulating GDF15 was linked to a reduction in food intake coupled with increased fecal energy loss, a distinct clustering of gut microbiota composition associated with higher microbial diversity, and transcriptional reprogramming of the ileal epithelium towards higher barrier function and antimicrobial defense. In conclusion, we show that in an obesogenic environment, endogenous GDF15 selectively prevents fat accumulation, spares lean mass and regulates energy assimilation with clear consequences for the gut microbial milieu and whole-body energy balance.

  • Open Access

    Publisher Correction: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

    by Daniela Liskiewicz, Aaron Novikoff, Ahmed Khalil, Seun Akindehin, Jonathan E. Campbell, Pietra Candela, Russell L. Castelino, Callum Coupland, Maxime Culot, W. Scott Dodson, et al.


  • Top Cited Papers
    Open Access

    GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

    by Daniela Liskiewicz, Aaron Novikoff, Ahmed Khalil, Seun Akindehin, Jonathan E. Campbell, Pietra Candela, Russell L. Castelino, Callum Coupland, Maxime Culot, W. Scott Dodson, et al.

    There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R–GIPR co-agonism is effective in the management of obesity and type 2 diabetes 1,2 , and lanifibranor—a nuclear-acting small-molecule triple agonist of PPARα, PPARγ and PPARδ—is in clinical phase 3 trials for the treatment of metabolic dysfunction-associated steatohepatitis 3 . Here, seeking to further improve the metabolic efficacy of GLP-1R–GIPR co-agonism, we report the development of a unimolecular quintuple agonist that combines the body weight-reducing and blood glucose-lowering effects of GLP-1R–GIPR co-agonism with the insulin-sensitizing and anti-inflammatory effects of lanifibranor via its targeted delivery into GLP-1R- and GIPR-expressing cells. In vitro, GLP-1–GIP–lanifibranor is indistinguishable from GLP-1–GIP in relation to incretin receptor signalling and shows equal stimulation of insulin secretion in isolated mouse islets. In vivo, however, GLP-1–GIP–lanifibranor outperforms GLP-1R–GIPR co-agonism and semaglutide, further decreasing body weight, food intake and hyperglycaemia in obese and insulin-resistant mice through synergistic incretin and PPAR action. The metabolic action of GLP-1–GIP–lanifibranor is blunted in mice with genetic or pharmacological inhibition of GLP-1R, GIPR or PPARδ and is absent in DIO double incretin receptor-knockout mice, collectively suggesting that GLP-1–GIP–lanifibranor has substantial therapeutic value in the treatment of obesity and diabetes.


  • Open Access

    Pantothenate kinase 4 controls skeletal muscle substrate metabolism

    by Adriana Miranda-Cervantes, Andreas M. Fritzen, Steffen H. Raun, Ondřej Hodek, Lisbeth L. V. Møller, Kornelia Johann, Luisa Deisen, Paul Gregorevic, Anders Gudiksen, Anna Artati, et al.

    Metabolic flexibility in skeletal muscle is essential for maintaining healthy glucose and lipid metabolism, and its dysfunction is closely linked to metabolic diseases. Exercise enhances metabolic flexibility, making it an important tool for discovering mechanisms that promote metabolic health. Here we show that pantothenate kinase 4 (PanK4) is a new conserved exercise target with high abundance in muscle. Muscle-specific deletion of PanK4 impairs fatty acid oxidation which is related to higher intramuscular acetyl-CoA and malonyl-CoA levels. Elevated acetyl-CoA levels persist regardless of feeding state and are associated with whole-body glucose intolerance, reduced insulin-stimulated glucose uptake in glycolytic muscle, and impaired glucose uptake during exercise. Conversely, increasing PanK4 levels in glycolytic muscle lowers acetyl-CoA and enhances glucose uptake. Our findings highlight PanK4 as an important regulator of acetyl-CoA levels, playing a key role in both muscle lipid and glucose metabolism.


  • Open Access

    NDRG1 is induced by antigen-receptor signaling but dispensable for B and T cell self-tolerance

    by Rose Hodgson, Xijin Xu, Consuelo Anzilotti, Mukta Deobagkar-Lele, Tanya L. Crockford, Jessica D. Kepple, Eleanor Cawthorne, Aneesha Bhandari, Alberto Cebrian-Serrano, Martin J. Wilcock, et al.

    Peripheral tolerance prevents the initiation of damaging immune responses by autoreactive lymphocytes. While tolerogenic mechanisms are tightly regulated by antigen-dependent and independent signals, downstream pathways are incompletely understood. N-myc downstream-regulated gene 1 (NDRG1), an anti-cancer therapeutic target, has previously been implicated as a CD4+T cell clonal anergy factor. By RNA-sequencing, we identifiedNdrg1as the third most upregulated gene in anergic, compared to naïve follicular, B cells.Ndrg1is upregulated by B cell receptor activation (signal one) and suppressed by co-stimulation (signal two), suggesting that NDRG1 may be important in B cell tolerance. However, thoughNdrg1−/−mice have a neurological defect mimicking NDRG1-associated Charcot-Marie-Tooth (CMT4d) disease, primary and secondary immune responses were normal. We find that B cell tolerance is maintained, and NDRG1 does not play a role in downstream responses during re-stimulation of in vivo antigen-experienced CD4+T cells, demonstrating that NDGR1 is functionally redundant for lymphocyte anergy.


  • Open Access

    Effect of number of oocytes and embryos on in vitro oocyte maturation, fertilization and embryo development in bovine

    by I. Salvador, A. Cebrian-Serrano, D. Salamone, M. A. Silvestre

    The aim of this study was to identify the in vitro development stage at which the culture of a single or low number (n = 5 or 10) of oocytes/embryos could impair development in comparison with culture in group (n = 50). In the Experiment 1, it was confirmed that single in vitro embryo production yielded lower cleavage and blastocyst rates than in group (49.4 vs. 83.0%; 0% vs. 37.8%, respectively; p < 0.05). In Experiment 2 and 3, it was observed no effect on embryo development of culturing single or low number of oocytes during maturation and fertilization, respectively. In Experiment 4, it was observed a detrimental effect on blastocyst rate when cultured single or low number of embryos during post-fertilization in vitro culture (2.9; 10.2-10.8; 33.2% in single, low number of embryos (5-10), and controlgrouped, respectively; p < 0.05). In Experiment 5, it was observed that the last part of the culture period (day 3 onwards) seemed to be more affected by the low number of embryos placed in culture. In conclusion, post-fertilization culture, especially on days 3 to 7 after fertilization, seems to be the most important stage for embryo development on single and/or low number (5-10) of embryos culture.